

Gastro Services & Facilities

Dr John Gibbons MBBS (Qld) FRACP
Dr Kate Cayzer MBBS (Qld) PhD FRACP
Dr Jillian Rosenstengel MBBS (Qld) FRACP
Dr Nicholas Tutticci BSc MBBS (Qld Hons II)

REPLY EMAIL: EEC.nurse@easternendo.com

Date.....

Dear Dr.....,

Re: COLONOSCOPY for Name:.....

Date of Birth: on/...../.....at(Hospital)

All patients taking Sodium Glucose Co-transporter-2 inhibitor agents (**SGLT2i**) have an increased risk of developing **Severe Euglycaemic Ketoacidosis** whilst undergoing the fasting and possible dehydration associated with the preparation for their Colonoscopy. The recommendation from the **Australian & New Zealand College of Anaesthetists** and the **Australian Diabetes Society** is for **cessation of these drugs three (3) days pre-operatively.**

Sodium Glucose Co-transporter-2 inhibitor agents:

- FORXIGA- DAPAGLIFLOZIN.**
- XIGDUO - DAPAGLIFLOZIN + METFORMIN.**
- QTERN - DAPAGLIFLOZIN + SAXAGLIPTIN.**
- JARDIANCE - EMPAGLIFLOZIN.**
- GLYXAMBI - EMPAGLIFLOZIN + LINGLIPTIN.**
- JARDIAMET - EMPAGLIFLOZIN + METFORMIN.**
- STEGALATRO - ERTUGLIFLOZIN.**
- SEGLUROMET - ERTUGLIFLOZIN.**
- STEGLUJAN- ERTUGLIFLOZIN.**

As the treating doctor, please indicate below the advice given to your patient re cessation of these medications.

Date.....

- I have informed the patient to cease 3 days prior to the endoscopic procedure.

Signed.....Dr's Name (please print).....